Shashikant Srivastava1, Jotam G Pasipanodya2, Scott K Heysell3, Gunavanthi D Boorgula4, Tawanda Gumbo2, Pamela J McShane5, Julie V Philley5. 1. Department of Pulmonary Immunology, University of Texas at Tyler, Tyler, Texas, USA; Department of Immunology, UT Southwestern Medical Center, Dallas, Texas, USA; Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, Texas, USA. Electronic address: Shashi.kant@uthct.edu. 2. Quantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, Texas, USA. 3. Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA. 4. Department of Pulmonary Immunology, University of Texas at Tyler, Tyler, Texas, USA. 5. Section of Pulmonary and Critical Care, University of Texas at Tyler, Tyler, Texas, USA.
Abstract
OBJECTIVES: The aim of this study was to determine and compare the efficacy of drugs to treat Mycobacterium kansasii (Mkn) pulmonary disease by performing minimum inhibitory concentration (MIC) determination and time-kill studies. METHODS: We determined the MICs to 13 drugs against the Mkn standard laboratory strain ATCC 12478 and 20 clinical isolates and performed time-kill studies with 18 drugs from different classes using the standard laboratory strain of Mkn. The β-lactam antibiotics were tested with or without the combination of the β-lactamase inhibitor avibactam. An inhibitory sigmoid Emax model was used to describe the relationship between drug concentrations and bacterial burden. RESULTS: Among the 13 tested drugs in the MIC experiments, the lowest MIC was recorded for bedaquiline. Among the 18 drugs used in the time-kill studies, maximum kill with cefdinir, tebipenem, clarithromycin, azithromycin, moxifloxacin, levofloxacin, tedizolid, bedaquiline, pretomanid and telacebac was greater than that for some of the drugs (isoniazid, rifampicin and ethambutol) used in standard combination therapy. CONCLUSION: We report preclinical data on the efficacy and potency of drugs that can potentially be repurposed to create a safe, effective and likely shorter-duration regimen for the treatment of Mkn pulmonary disease.
OBJECTIVES: The aim of this study was to determine and compare the efficacy of drugs to treat Mycobacterium kansasii (Mkn) pulmonary disease by performing minimum inhibitory concentration (MIC) determination and time-kill studies. METHODS: We determined the MICs to 13 drugs against the Mkn standard laboratory strain ATCC 12478 and 20 clinical isolates and performed time-kill studies with 18 drugs from different classes using the standard laboratory strain of Mkn. The β-lactam antibiotics were tested with or without the combination of the β-lactamase inhibitor avibactam. An inhibitory sigmoid Emax model was used to describe the relationship between drug concentrations and bacterial burden. RESULTS: Among the 13 tested drugs in the MIC experiments, the lowest MIC was recorded for bedaquiline. Among the 18 drugs used in the time-kill studies, maximum kill with cefdinir, tebipenem, clarithromycin, azithromycin, moxifloxacin, levofloxacin, tedizolid, bedaquiline, pretomanid and telacebac was greater than that for some of the drugs (isoniazid, rifampicin and ethambutol) used in standard combination therapy. CONCLUSION: We report preclinical data on the efficacy and potency of drugs that can potentially be repurposed to create a safe, effective and likely shorter-duration regimen for the treatment of Mkn pulmonary disease.
Authors: Andreas H Diacon; Rodney Dawson; Madeleine Hanekom; Kim Narunsky; Stefan J Maritz; Amour Venter; Peter R Donald; Christo van Niekerk; Karl Whitney; Doris J Rouse; Martino W Laurenzi; Ann M Ginsberg; Melvin K Spigelman Journal: Antimicrob Agents Chemother Date: 2010-05-24 Impact factor: 5.191
Authors: Charles S Haworth; John Banks; Toby Capstick; Andrew J Fisher; Thomas Gorsuch; Ian F Laurenson; Andrew Leitch; Michael R Loebinger; Heather J Milburn; Mark Nightingale; Peter Ormerod; Delane Shingadia; David Smith; Nuala Whitehead; Robert Wilson; R Andres Floto Journal: Thorax Date: 2017-11 Impact factor: 9.139
Authors: L Davies Forsman; T Schön; U S H Simonsson; J Bruchfeld; M Larsson; P Juréen; E Sturegård; C G Giske; K Ängeby Journal: Antimicrob Agents Chemother Date: 2014-09-22 Impact factor: 5.191
Authors: Jan-Willem Alffenaar; Anne-Grete Märtson; Scott K Heysell; Jin-Gun Cho; Asad Patanwala; Gina Burch; Hannah Y Kim; Marieke G G Sturkenboom; Anthony Byrne; Debbie Marriott; Indy Sandaradura; Simon Tiberi; Vitali Sintchencko; Shashikant Srivastava; Charles A Peloquin Journal: Clin Pharmacokinet Date: 2021-03-10 Impact factor: 6.447
Authors: Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Patrick P J Phillips; Kia Bryant; Kelly E Dooley; Melissa Engle; Stefan V Goldberg; Ha T T Phan; James Hakim; John L Johnson; Madeleine Lourens; Neil A Martinson; Grace Muzanyi; Kim Narunsky; Sandy Nerette; Nhung V Nguyen; Thuong H Pham; Samuel Pierre; Anne E Purfield; Wadzanai Samaneka; Radojka M Savic; Ian Sanne; Nigel A Scott; Justin Shenje; Erin Sizemore; Andrew Vernon; Ziyaad Waja; Marc Weiner; Susan Swindells; Richard E Chaisson Journal: N Engl J Med Date: 2021-05-06 Impact factor: 176.079